drugset / Trial / NCT00116662

An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

NCT00116662

Phase 2 Completed 84 enrolled Graceway Pharmaceuticals, LLC
Non-randomizedSingle-groupSingle-blindTreatment

Summary

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.

Timeline

Start
2005-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule Topical

Indications